Variagenics, inc.
Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care. Toward this end, the company analyzes genetic variations in both normal and tumor cells, including SNPs, haplotypes, loss of heterozygosity, and gene expression levels. The company's approach of analyzing multiple types of genetic variations increases the likelihood of finding significant associations with drug response and successfully developing diagnostics. Variagenics is pursuing marker identification and diagnostic development through both biopharmaceutical collaborations and internal research programs.
Ferentz
Ann E
AE
Variagenics, Inc., 60 Hampshire Street Cambridge MA 02139, USA. aferentz@variagenics.com
Mohr
Joseph S
JS
D000970:Antineoplastic Agents / Q000008:administration & dosage; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods* / Q000639:trends
D000970:Antineoplastic Agents